MeiraGTx Reports Q1 Revenue of $293,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Reports Q1 revenue $293,000 vs. $1.93M last year. "Our achievements in the first few months of 2026 have materially strengthened MeiraGTx - we are now in a position to file for potential approval and launch two wholly-owned therapies in the next 2 years," said Alexandria Forbes, president and chief executive officer of MeiraGTx. "The compelling three-year durability data from our AAV2-hAQP1 Phase 1 study continue to demonstrate disease-modifying benefit following a simple one-time treatment of patients with moderate to severe persistent radiation-induced xerostomia, an otherwise debilitating life-long condition. The recent receipt of Breakthrough Therapy Designation for this program reinforces the strength of the data and the potential for an expedited development and regulatory pathway."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MGTX
Wall Street analysts forecast MGTX stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.920
Low
14.00
Averages
21.50
High
30.00
Current: 13.920
Low
14.00
Averages
21.50
High
30.00
About MGTX
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MeiraGTx Secures Up to $400 Million Investment from Oberland Capital
- Significant Investment: MeiraGTx has entered into an agreement with Oberland Capital for up to $400 million in funding, including $375 million in non-dilutive capital and $25 million in equity, reflecting strong market confidence in its product pipeline.
- High Product Potential: The investment will support the commercialization of three potentially approvable therapies, particularly for XLRP and radiation-induced xerostomia, expected to gain approval within the next 12 to 24 months, addressing a large unmet medical need.
- Flexible Funding Structure: Oberland Capital's investment includes low single-digit royalties, allowing MeiraGTx to secure substantial non-dilutive capital while maintaining business flexibility, which is crucial for effective product launch strategies.
- Future Growth Prospects: MeiraGTx's innovative technology platform and extensive clinical programs position it as a leader in gene therapy, with this investment further enhancing its competitive edge in the global market, especially in addressing significant disease needs.
See More
MeiraGTx Secures Up to $400M Funding for Gene Therapy Development
- Funding Agreement: MeiraGTx Holdings (MGTX) has entered into an agreement with Oberland Capital Management to secure up to $400 million in funding, which is expected to significantly enhance the company's research and development capabilities and market competitiveness in gene therapy.
- Cash Injection Details: Under the agreement, Oberland Capital will provide MeiraGTx with $375 million in cash in exchange for low-single-digit royalties on future net sales of experimental therapies, including AAV2-hAQP1, bota-vec, and AAV-AIPL1, ensuring a stable cash flow for the company.
- Equity Investment Commitment: Oberland Capital has also committed to invest up to $25 million in MeiraGTx, starting with a $10 million equity investment and the right to purchase an additional $15 million in equity in the future, demonstrating confidence in the company's growth potential.
- Positive Market Reaction: Following the funding announcement, MeiraGTx's shares rose approximately 7% in premarket trading, reflecting investor confidence in the company's gene therapy projects and optimistic market expectations for its future development.
See More
MeiraGTx Secures Up to $400 Million Investment from Oberland Capital
- Investment Agreement Details: MeiraGTx Holdings has entered into an agreement with Oberland Capital Management for an investment of up to $400 million, which includes $375 million in non-dilutive royalty financing and $25 million in equity investment, reflecting strong market confidence in its gene therapy programs.
- Initial Funding Arrangement: The initial funding of $135 million consists of $125 million in royalty financing and $10 million in equity investment, providing crucial financial support for the company's gene therapy initiatives.
- Future Funding Potential: MeiraGTx could access up to $265 million in additional funding based on clinical data, regulatory approvals, and future business development opportunities, which will further propel the development and commercialization of its gene therapy programs.
- Royalty Rights Arrangement: Oberland will receive capped low single-digit royalties on sales of MeiraGTx's therapies following regulatory approvals, which not only provides financial backing for the company but also incentivizes Oberland to engage in the marketing of its products.
See More
MeiraGTx Q1 Earnings Miss Expectations
- Earnings Report Shortfall: MeiraGTx reported a Q1 GAAP EPS of -$0.57, missing expectations by $0.18, indicating challenges in profitability that may affect investor confidence moving forward.
- Significant Revenue Decline: The company’s Q1 revenue of $0.29M represents an 85.0% year-over-year decrease, reflecting a substantial drop in product sales or service demand, which could negatively impact future cash flows.
- Increased Cash Reserves: As of March 31, 2026, MeiraGTx's cash, cash equivalents, and restricted cash totaled $73.8M, up from $68.2M as of December 31, 2025, indicating improvements in cash management practices.
- Future Financing Plans: MeiraGTx is eyeing a $100M equity offering following its gene therapy deal with Johnson & Johnson, aimed at strengthening its capital base to support ongoing R&D and commercialization efforts.
See More
MeiraGTx Prices $100M Equity Offering to Acquire Gene Therapy bota-vec
- Equity Offering: MeiraGTx Holdings (MGTX) plans to raise nearly $100 million by pricing an offering of approximately 11.1 million shares at $9.00 each, reflecting the company's confidence in funding the market launch of its gene therapy bota-vec.
- Asset Purchase Agreement: The company has entered into an asset purchase agreement with Johnson & Johnson (JNJ) to acquire bota-vec related to X-linked retinitis pigmentosa, with JNJ receiving $25 million upfront and a milestone payment tied to U.S. approval and sales performance, indicating JNJ's commitment to the product.
- Future Royalties: Under the agreement, beginning mid-2029, JNJ will receive high double-digit royalties based on worldwide net sales of bota-vec, which could provide long-term revenue support for MeiraGTx while underscoring JNJ's confidence in the product's market potential.
- Regulatory Submission Plans: MeiraGTx stated it will immediately file global regulatory submissions for bota-vec approval, with a commercial launch expected in H2 2028, demonstrating the company's strategic positioning and intent to expand in the gene therapy market.
See More
MeiraGTx Acquires bota-vec from J&J for XLRP Treatment
- Asset Purchase Agreement: MeiraGTx has entered into an agreement with Johnson & Johnson to acquire bota-vec for $25 million, significantly enhancing its market position in the treatment of X-linked retinitis pigmentosa (XLRP).
- Global Regulatory Filings: The company intends to immediately pursue global regulatory filings for bota-vec, aiming for a potential launch in 2027, addressing the urgent treatment needs of over 20,000 XLRP patients, which presents substantial market potential.
- Clinical Trial Data Support: The LUMEOS Phase 3 study demonstrated significant improvements in low luminance visual acuity with bota-vec, with many patients reporting real-world benefits, providing strong support for regulatory approval.
- Strategic Development Goals: By reacquiring bota-vec, MeiraGTx not only strengthens its product pipeline but also plans to launch two products targeting severe unmet needs within the next two years, further solidifying its leadership in the gene therapy sector.
See More
MeiraGTx Secures Up to $400 Million Investment from Oberland Capital
- Significant Investment: MeiraGTx has entered into an agreement with Oberland Capital for up to $400 million in funding, including $375 million in non-dilutive capital and $25 million in equity, reflecting strong market confidence in its product pipeline.
- High Product Potential: The investment will support the commercialization of three potentially approvable therapies, particularly for XLRP and radiation-induced xerostomia, expected to gain approval within the next 12 to 24 months, addressing a large unmet medical need.
- Flexible Funding Structure: Oberland Capital's investment includes low single-digit royalties, allowing MeiraGTx to secure substantial non-dilutive capital while maintaining business flexibility, which is crucial for effective product launch strategies.
- Future Growth Prospects: MeiraGTx's innovative technology platform and extensive clinical programs position it as a leader in gene therapy, with this investment further enhancing its competitive edge in the global market, especially in addressing significant disease needs.
See More
MeiraGTx Secures Up to $400M Funding for Gene Therapy Development
- Funding Agreement: MeiraGTx Holdings (MGTX) has entered into an agreement with Oberland Capital Management to secure up to $400 million in funding, which is expected to significantly enhance the company's research and development capabilities and market competitiveness in gene therapy.
- Cash Injection Details: Under the agreement, Oberland Capital will provide MeiraGTx with $375 million in cash in exchange for low-single-digit royalties on future net sales of experimental therapies, including AAV2-hAQP1, bota-vec, and AAV-AIPL1, ensuring a stable cash flow for the company.
- Equity Investment Commitment: Oberland Capital has also committed to invest up to $25 million in MeiraGTx, starting with a $10 million equity investment and the right to purchase an additional $15 million in equity in the future, demonstrating confidence in the company's growth potential.
- Positive Market Reaction: Following the funding announcement, MeiraGTx's shares rose approximately 7% in premarket trading, reflecting investor confidence in the company's gene therapy projects and optimistic market expectations for its future development.
See More
MeiraGTx Secures Up to $400 Million Investment from Oberland Capital
- Investment Agreement Details: MeiraGTx Holdings has entered into an agreement with Oberland Capital Management for an investment of up to $400 million, which includes $375 million in non-dilutive royalty financing and $25 million in equity investment, reflecting strong market confidence in its gene therapy programs.
- Initial Funding Arrangement: The initial funding of $135 million consists of $125 million in royalty financing and $10 million in equity investment, providing crucial financial support for the company's gene therapy initiatives.
- Future Funding Potential: MeiraGTx could access up to $265 million in additional funding based on clinical data, regulatory approvals, and future business development opportunities, which will further propel the development and commercialization of its gene therapy programs.
- Royalty Rights Arrangement: Oberland will receive capped low single-digit royalties on sales of MeiraGTx's therapies following regulatory approvals, which not only provides financial backing for the company but also incentivizes Oberland to engage in the marketing of its products.
See More
MeiraGTx Q1 Earnings Miss Expectations
- Earnings Report Shortfall: MeiraGTx reported a Q1 GAAP EPS of -$0.57, missing expectations by $0.18, indicating challenges in profitability that may affect investor confidence moving forward.
- Significant Revenue Decline: The company’s Q1 revenue of $0.29M represents an 85.0% year-over-year decrease, reflecting a substantial drop in product sales or service demand, which could negatively impact future cash flows.
- Increased Cash Reserves: As of March 31, 2026, MeiraGTx's cash, cash equivalents, and restricted cash totaled $73.8M, up from $68.2M as of December 31, 2025, indicating improvements in cash management practices.
- Future Financing Plans: MeiraGTx is eyeing a $100M equity offering following its gene therapy deal with Johnson & Johnson, aimed at strengthening its capital base to support ongoing R&D and commercialization efforts.
See More
MeiraGTx Prices $100M Equity Offering to Acquire Gene Therapy bota-vec
- Equity Offering: MeiraGTx Holdings (MGTX) plans to raise nearly $100 million by pricing an offering of approximately 11.1 million shares at $9.00 each, reflecting the company's confidence in funding the market launch of its gene therapy bota-vec.
- Asset Purchase Agreement: The company has entered into an asset purchase agreement with Johnson & Johnson (JNJ) to acquire bota-vec related to X-linked retinitis pigmentosa, with JNJ receiving $25 million upfront and a milestone payment tied to U.S. approval and sales performance, indicating JNJ's commitment to the product.
- Future Royalties: Under the agreement, beginning mid-2029, JNJ will receive high double-digit royalties based on worldwide net sales of bota-vec, which could provide long-term revenue support for MeiraGTx while underscoring JNJ's confidence in the product's market potential.
- Regulatory Submission Plans: MeiraGTx stated it will immediately file global regulatory submissions for bota-vec approval, with a commercial launch expected in H2 2028, demonstrating the company's strategic positioning and intent to expand in the gene therapy market.
See More
MeiraGTx Acquires bota-vec from J&J for XLRP Treatment
- Asset Purchase Agreement: MeiraGTx has entered into an agreement with Johnson & Johnson to acquire bota-vec for $25 million, significantly enhancing its market position in the treatment of X-linked retinitis pigmentosa (XLRP).
- Global Regulatory Filings: The company intends to immediately pursue global regulatory filings for bota-vec, aiming for a potential launch in 2027, addressing the urgent treatment needs of over 20,000 XLRP patients, which presents substantial market potential.
- Clinical Trial Data Support: The LUMEOS Phase 3 study demonstrated significant improvements in low luminance visual acuity with bota-vec, with many patients reporting real-world benefits, providing strong support for regulatory approval.
- Strategic Development Goals: By reacquiring bota-vec, MeiraGTx not only strengthens its product pipeline but also plans to launch two products targeting severe unmet needs within the next two years, further solidifying its leadership in the gene therapy sector.
See More
